Differences in risk profiles and long-term outcomes in acute heart failure patients with preserved and reduced left ventricular ejection fraction in the Czech Republic: The AHEAD registry sub-analysis.


Journal

Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia
ISSN: 1804-7521
Titre abrégé: Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
Pays: Czech Republic
ID NLM: 101140142

Informations de publication

Date de publication:
Mar 2021
Historique:
received: 14 06 2020
accepted: 04 09 2020
pubmed: 7 10 2020
medline: 4 11 2021
entrez: 6 10 2020
Statut: ppublish

Résumé

The latest European heart failure guidelines define patients as those with reduced (HFrEF), mid-range, and preserved (HFpEF) left ventricular ejection fraction (LVEF; <40%, 40%-49%, and ≥50%, respectively). We investigated the causes of rehospitalizations/deaths in our institution's heart failure patients and focused on differences in the clinical presentation, risk profile, and long-term outcomes between the HFrEF and HFpEF groups in a real-life scenario. We followed 1274 patients discharged from heart failure hospitalization in 2 centres. The mean patient age was 75.9 years, and men and women were represented equally. During the minimal follow-up of 2 years, 57% of patients were hospitalised for any cause, 24.9% for decompensated heart failure, and 43.3% for any cardiovascular cause. A total of 36.1% of patients died, either with prior (11.8%) or without prior (24.3%) heart failure rehospitalization. Heart failure was also the most frequent cause of cardiovascular hospitalization, followed by gastrointestinal problems, infections, and tumours for noncardiovascular hospitalizations. Patients with HFrEF had different baseline characteristics and risk profiles, experienced more hospitalizations for acute heart failure (28.6% vs 20.2%, P=0.012), and had higher cardiovascular mortality (82.4% vs 63.5%, P<0.001) when compared with HFpEF patients. Overall mortality and rehospitalization rates were similar. Within 2 years, half of the patients died and/or were hospitalised for acute decompensation of heart failure, and only one-third of the patients survived without any hospitalization. HFrEF and HFpEF patients were confirmed to be different entities with diverse characteristics, risk profiles, and cardiovascular event rates.

Sections du résumé

BACKGROUND BACKGROUND
The latest European heart failure guidelines define patients as those with reduced (HFrEF), mid-range, and preserved (HFpEF) left ventricular ejection fraction (LVEF; <40%, 40%-49%, and ≥50%, respectively). We investigated the causes of rehospitalizations/deaths in our institution's heart failure patients and focused on differences in the clinical presentation, risk profile, and long-term outcomes between the HFrEF and HFpEF groups in a real-life scenario.
METHODS AND RESULTS RESULTS
We followed 1274 patients discharged from heart failure hospitalization in 2 centres. The mean patient age was 75.9 years, and men and women were represented equally. During the minimal follow-up of 2 years, 57% of patients were hospitalised for any cause, 24.9% for decompensated heart failure, and 43.3% for any cardiovascular cause. A total of 36.1% of patients died, either with prior (11.8%) or without prior (24.3%) heart failure rehospitalization. Heart failure was also the most frequent cause of cardiovascular hospitalization, followed by gastrointestinal problems, infections, and tumours for noncardiovascular hospitalizations. Patients with HFrEF had different baseline characteristics and risk profiles, experienced more hospitalizations for acute heart failure (28.6% vs 20.2%, P=0.012), and had higher cardiovascular mortality (82.4% vs 63.5%, P<0.001) when compared with HFpEF patients. Overall mortality and rehospitalization rates were similar.
CONCLUSION CONCLUSIONS
Within 2 years, half of the patients died and/or were hospitalised for acute decompensation of heart failure, and only one-third of the patients survived without any hospitalization. HFrEF and HFpEF patients were confirmed to be different entities with diverse characteristics, risk profiles, and cardiovascular event rates.

Identifiants

pubmed: 33020669
doi: 10.5507/bp.2020.038
doi:

Types de publication

Comparative Study Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

34-42

Auteurs

Roman Miklik (R)

Cardiology, Podlesi Hospital Trinec, Czech Republic.
Internal Department, Military Hospital Brno, Czech Republic.

Marie Miklikova (M)

Department of Cardiology, University Hospital Brno, Czech Republic.
Medical Faculty, Masaryk University, Brno, Czech Republic.

Radim Spacek (R)

Department of Internal Medicine, Hospital Frydek-Mistek, Frydek-Mistek, Czech Republic.

Jindrich Spinar (J)

Department of Cardiology, University Hospital Brno, Czech Republic.
Medical Faculty, Masaryk University, Brno, Czech Republic.

Kamil Zeman (K)

Department of Internal Medicine, Hospital Frydek-Mistek, Frydek-Mistek, Czech Republic.

Klara Benesova (K)

Institute of Biostatistics and Analysis, Faculty of Medicine, Masaryk University, Brno, Czech Republic.

Marian Felsoci (M)

Department of Cardiology, University Hospital Brno, Czech Republic.

Lidka Pohludkova (L)

Department of Internal Medicine, Hospital Frydek-Mistek, Frydek-Mistek, Czech Republic.

Ladislav Dusek (L)

Institute of Biostatistics and Analysis, Faculty of Medicine, Masaryk University, Brno, Czech Republic.

Jiri Jarkovsky (J)

Institute of Biostatistics and Analysis, Faculty of Medicine, Masaryk University, Brno, Czech Republic.

Petr Lokaj (P)

Department of Cardiology, University Hospital Brno, Czech Republic.
Medical Faculty, Masaryk University, Brno, Czech Republic.

Ilona Parenicova (I)

Centre of Cardiovascular and Transplant Surgery, Pekarska 53, Brno, Czech Republic.

Jiri Parenica (J)

Department of Cardiology, University Hospital Brno, Czech Republic.
Medical Faculty, Masaryk University, Brno, Czech Republic.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH